A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma
Sarcoma, Kaposi, HIV Infections
About this trial
This is an interventional treatment trial for Sarcoma, Kaposi focused on measuring AIDS-Related Opportunistic Infections, Sarcoma, Kaposi, Antineoplastic Agents
Eligibility Criteria
Inclusion Criteria Patients must have: HIV positive status and histologic confirmation of KS. CD4 count > 200 mm3 (required of one-half of patients). Minimum of 6 mucocutaneous KS lesions, including at least 3 raised lesions meeting criteria for "indicator" lesions. Acceptable organ system function. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Serious or intercurrent illness or infection that would interfere with the ability of the patient to carry out the treatment program. Prior Medication: Excluded: Systemic therapy for KS within 30 days. Local or topical therapy for KS indicative lesions within 60 days. Systemic therapy with vitamin A in doses exceeding 15,000 IU per day or other retinoid class drug. Required: Approved antiretroviral therapy.